Sugi Predict

Sugi Predict / Compounds / SCHEMBL999679

SCHEMBL999679

SCHEMBL999679

CC(C)(C)OC(=O)NC1CCCCC1=O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.50
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ BTK Q06187 1/20 0.44
▸ EPHX1 P07099 1/20 0.42
▸ F2 P00734 1/20 0.39
▸ F10 P00742 1/20 0.39
▸ PRSS1 P07477 1/20 0.39
▸ CTSK P43235 2/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CCR2 P41597 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25981811 1.00 GAA (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL9932237 1.00 GAA (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL24818982 0.95 GAA (0.51) GAANFKB1NFKB2RELABTK
SCHEMBL15192054 0.95 GAA (0.51) GAANFKB1NFKB2RELABTK
SCHEMBL764580 0.95 GAA (0.51) GAANFKB1NFKB2RELABTK
SCHEMBL2771992 0.88 GAA (0.54) GAANFKB1NFKB2RELABTK
SCHEMBL3621203 0.88 GAA (0.54) GAANFKB1NFKB2RELABTK
SCHEMBL16782174 0.83 GAA (0.46) GAANFKB1NFKB2RELABTK
SCHEMBL16782405 0.83 GAA (0.46) GAANFKB1NFKB2RELABTK
SCHEMBL28573430 0.80 GAA (0.50) GAANFKB1NFKB2RELABTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559487-B2 Crosslinked optically active secondary amine derivative Sumitomo Pharma Co., Ltd. (JP) 2026-02-24 — — US disclosed
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-31 — — US disclosed
US-20220380365-A1 CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-12-01 — — US disclosed
US-11389464-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2022-07-19 — — US disclosed
WO-2021060453-A1 CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE 大日本住友製薬株式会社 2021-04-01 — — WO disclosed
EP-3719024-A1 ARGINASE INHIBITORS AS THERAPEUTICS Mars, Incorporated (US) 2020-10-07 — — EP disclosed
US-20200246362-A1 Arginase Inhibitors as Therapeutics MARS, INCORPORATED 2020-08-06 — — US disclosed
CN-106008569-B9 Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-05-22 — — CN disclosed
EP-3034509-B1 ARGINASE INHIBITORS AS THERAPEUTICS MARS INC (US) 2020-04-22 — — EP disclosed
CN-106008569-B Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-04-03 — — CN disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 — — US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 — — US disclosed
WO-2005066145-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-07-21 — — WO disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 — — US disclosed
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. 2005-02-10 — — US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 — — US disclosed
CN-1468217-A Aliphatic nitrogenous five-membered ring compounds ������ҩ��ʽ���� 2004-01-14 — — CN disclosed
EP-1317445-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 — — EP disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 — — US disclosed
WO-2002022600-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11389464-B2 Arginase inhibitors as therapeutics ARG1, ARG2, PRMT1 GAA 282/4885NFKB1 2340/4885NFKB2 1894/4885
US-20220380365-A1 CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE MLLT3, MLLT1, MEN1 GAA 4877/4885NFKB1 3187/4885NFKB2 3437/4885
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 GAA 4680/4885NFKB1 543/4885NFKB2 780/4885
US-12559487-B2 Crosslinked optically active secondary amine derivative MLLT3, MLLT1, FLI1 GAA 4840/4885NFKB1 3736/4885NFKB2 3813/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 GAA 4607/4885NFKB1 730/4885NFKB2 974/4885
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 GAA 771/4885NFKB1 962/4885NFKB2 797/4885
US-20200246362-A1 Arginase Inhibitors as Therapeutics ARG1, ARG2, PRMT1 GAA 282/4885NFKB1 2340/4885NFKB2 1894/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 GAA 4680/4885NFKB1 543/4885NFKB2 780/4885
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors CBR3, CBR1, PDE9A GAA 3723/4885NFKB1 3546/4885NFKB2 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.